Conjugated anti-TF mAb (a chimeric antibody composed of clone 1849 variable domains and constant human domains) to immunomicelles exhibits higher anti-cancer potential toward TF-positive stomach cancer compared to the anti-TF mAb and NC-6300 combination; it can be distributed more equally among TF-positive tumor tissue in comparison with NC-6300. This evidence concerns the gene TF and cancer.